<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7506210\results\search\zoonosis\results.xml">
  <result pre="and cause disease. The 2019 novel coronavirus (SARS-CoV-2), which causes" exact="Coronavirus disease 2019" post="(COVID-19), is the seventh known coronavirus to infect humans."/>
  <result pre="cause only mild to moderate upper respiratory disease in humans." exact="Severe acute respiratory syndrome" post="(SARS) is a viral respiratory illness caused by SARS-CoV,"/>
  <result pre="COVID-19 refers to the respiratory symptoms and pneumonia caused by" exact="SARS-CoV-2 infection." post="By Sep 18, 2020, according to WHO, SARS-CoV-2 had"/>
  <result pre="80R scFv can neutralize &amp;gt;50% of the testing wells from" exact="SARS-CoV infection." post="In most cases, the bivalent full-length immunoglobulin is more"/>
  <result pre="a further study, 80R IgG1 could efficiently protect mice from" exact="SARS-CoV infection," post="noting that the core of its target is aa"/>
  <result pre="SARS-CoV in vitro. The NMAb 201 completely protected mice against" exact="SARS-CoV infection" post="at a concentration of 40â€‰mg/kg. In doses as low"/>
  <result pre="the RBD of SARS-CoV S protein,23 suggesting that F26G18 neutralizes" exact="SARS-CoV infection" post="by blocking RBD-ACE2 the binding. Using hybridoma technology, 26"/>
  <result pre="(human ACE2) for binding to RBD, indicating that ab1 neutralizes" exact="SARS-CoV-2 infection" post="by blocking RBD-ACE2 binding. The ab1 IgG1 could completely"/>
  <result pre="determined by sequence alignment results. This indicates that either natural" exact="SARS-CoV-2 infection" post="or RBD-based vaccines could stimulate the quick production of"/>
  <result pre="overlap with the RBD-ACE2 binding interface, suggesting that B38 neutralizes" exact="SARS-CoV-2 infection" post="by functionally mimicking ACE2 to bind RBD and block"/>
  <result pre="with an IC50 value of 8â€‰ng/ml and potently inhibited live" exact="SARS-CoV-2 infection" post="with IC50 values of 7 and 9â€‰ng/ml, respectively. To"/>
  <result pre="neutralization assay showed that H11-H4-Fc and H11-D4-Fc could neutralize live" exact="SARS-CoV-2 infection" post="with the ND50 of 6â€‰nM and 18â€‰nM, respectively. Combining"/>
  <result pre="to S protein and exhibited synergistic neutralization effect on live" exact="SARS-CoV-2 infection." post="The use of COV2-2196 and COV2-2130 alone or in"/>
  <result pre="have IC50 in a range 0.7 ~ 9â€‰ng/ml against live" exact="SARS-CoV-2 infection." post="Among of them, 2â€&quot;15, 2â€&quot;7, 1â€&quot;57, and 1â€&quot;20 targeted"/>
  <result pre="The most potent NMAb 2â€&quot;15 could neutralize pseudotyped and live" exact="SARS-CoV-2 infection" post="with IC50 of 5â€‰ng/ml and 0.7â€‰ng/ml, respectively, by binding"/>
  <result pre="been used successfully for the treatment of patients infected with" exact="Ebola" post="virus.57 Among NMAbs we discussed, there are some NMAbs"/>
  <result pre="coronavirus (SARS-CoV-2)?PLoS Pathog.202016e100842132407364 69.ZhangJet al.Evolving epidemiology and transmission dynamics of" exact="coronavirus disease 2019" post="outside Hubei province, China: a descriptive and modelling studyLancet"/>
  <result pre="areaJAMA20032892801280912734147 71.ChenNet al.Epidemiological and clinical characteristics of 99 cases of" exact="2019 novel coronavirus pneumonia" post="in Wuhan, China: a descriptive studyLancet202039550751332007143"/>
 </snippets>
</snippetsTree>
